NO20043799L - 2-oksasolaminer og deres anvendelse som 5-HT2B reseptor antagonister - Google Patents

2-oksasolaminer og deres anvendelse som 5-HT2B reseptor antagonister

Info

Publication number
NO20043799L
NO20043799L NO20043799A NO20043799A NO20043799L NO 20043799 L NO20043799 L NO 20043799L NO 20043799 A NO20043799 A NO 20043799A NO 20043799 A NO20043799 A NO 20043799A NO 20043799 L NO20043799 L NO 20043799L
Authority
NO
Norway
Prior art keywords
oxazolamines
receptor antagonists
ht2b receptor
ht2b
antagonists
Prior art date
Application number
NO20043799A
Other languages
English (en)
Other versions
NO327465B1 (no
Inventor
Alexander William Oxford
Neil Victor Harris
Anthony Richard Borman
Lyle Kenneth Clark
Ann Janet Archer
George Hynd
Amanda Aley
Original Assignee
Pharmagene Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmagene Lab Ltd filed Critical Pharmagene Lab Ltd
Publication of NO20043799L publication Critical patent/NO20043799L/no
Publication of NO327465B1 publication Critical patent/NO327465B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20043799A 2002-02-13 2004-09-10 2-oksasolaminer og deres anvendelse samt farmasoytisk sammensetning NO327465B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0203412.2A GB0203412D0 (en) 2002-02-13 2002-02-13 5-HT 2B receptor antagonists
PCT/GB2003/000552 WO2003068226A1 (en) 2002-02-13 2003-02-11 2-oxazolamines and their use as 5-ht2b receptor antagonists

Publications (2)

Publication Number Publication Date
NO20043799L true NO20043799L (no) 2004-09-10
NO327465B1 NO327465B1 (no) 2009-07-06

Family

ID=9930999

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043799A NO327465B1 (no) 2002-02-13 2004-09-10 2-oksasolaminer og deres anvendelse samt farmasoytisk sammensetning

Country Status (17)

Country Link
US (1) US7429607B2 (no)
EP (1) EP1474140B1 (no)
JP (1) JP4439266B2 (no)
KR (1) KR20040084905A (no)
CN (1) CN1633291A (no)
AU (1) AU2003207297B2 (no)
CA (1) CA2472762A1 (no)
DE (1) DE60317632T2 (no)
EA (1) EA200401077A1 (no)
GB (1) GB0203412D0 (no)
IL (1) IL163110A (no)
MX (1) MXPA04007738A (no)
NO (1) NO327465B1 (no)
NZ (1) NZ534539A (no)
PL (1) PL370221A1 (no)
WO (1) WO2003068226A1 (no)
ZA (1) ZA200406010B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1299948B1 (it) 1998-04-02 2000-04-04 Azionaria Costruzioni Acma Spa Metodo e dispositivo per la formazione di gruppi di articoli appiattiti.
US20050176791A1 (en) * 2002-02-13 2005-08-11 Oxford Alexander W. 5-HT2B receptor antagonists
US20090018150A1 (en) * 2003-07-24 2009-01-15 Asterand Uk Limited 5-Ht2b Receptor Antagonists
WO2005079845A1 (ja) 2004-02-20 2005-09-01 Astellas Pharma Inc. 片頭痛予防薬
SE0400850D0 (sv) * 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
WO2005097113A2 (en) * 2004-04-08 2005-10-20 Pharmagene Laboratories Limited 5-ht2b receptor antagonists
KR101381454B1 (ko) 2004-09-29 2014-04-04 바이엘 인텔렉쳐 프로퍼티 게엠베하 열역학적으로 안정한 형태의 bay 43-9006 토실레이트
WO2014085413A1 (en) * 2012-11-28 2014-06-05 Temple University - Of The Commonwealth System Of Higher Education Disubstituted oxazolidin-2-ones 5-hydroxytryptamine receptor 2b activity modulators
KR101592068B1 (ko) 2013-11-08 2016-02-05 순천향대학교 산학협력단 플라즈마 아포리포프로테인 h를 포함하는 아스피린 과민성 호흡계 질환 및 아스피린 내성 천식 구별 진단용 마커 및 구별 진단용 키트
CN116789549A (zh) * 2023-06-16 2023-09-22 山东科源化工有限公司 一种羟基乙酸乙烯酯的制备工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0658559A1 (de) * 1993-12-14 1995-06-21 Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. Thienothiazinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als 5-dipoxygenase und Cyclooxygenaseinhibitoren
US5663178A (en) 1995-02-06 1997-09-02 Eli Lilly And Company Tetrahydro-beta carbolines
CZ264996A3 (cs) 1994-03-11 1998-01-14 Eli Lilly And Company Použití sloučenin, které jsou aktivní na 5HT2B receptor
AU2177797A (en) * 1996-04-03 1997-10-22 Takeda Chemical Industries Ltd. Oxazole derivatives, their production and use
US5952331A (en) 1996-05-23 1999-09-14 Syntex (Usa) Inc. Aryl pyrimidine derivatives
TW440563B (en) * 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
US5958934A (en) 1996-05-23 1999-09-28 Syntex (U.S.A.) Inc. Aryl pyrimidine derivatives and uses thereof
WO2000023444A1 (en) * 1998-10-21 2000-04-27 Abbott Laboratories 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
CA2378710A1 (en) 1999-07-30 2001-02-08 Pharmagene Laboratories Ltd. Use of 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine in the treatment of gi disorders
AR035016A1 (es) * 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.

Also Published As

Publication number Publication date
JP4439266B2 (ja) 2010-03-24
DE60317632D1 (de) 2008-01-03
PL370221A1 (en) 2005-05-16
GB0203412D0 (en) 2002-04-03
US7429607B2 (en) 2008-09-30
JP2005528341A (ja) 2005-09-22
EP1474140A1 (en) 2004-11-10
NO327465B1 (no) 2009-07-06
AU2003207297B2 (en) 2008-11-06
EP1474140B1 (en) 2007-11-21
CA2472762A1 (en) 2003-08-21
MXPA04007738A (es) 2004-10-15
AU2003207297A2 (en) 2003-09-04
CN1633291A (zh) 2005-06-29
AU2003207297A1 (en) 2003-09-04
ZA200406010B (en) 2005-06-08
EA200401077A1 (ru) 2005-06-30
NZ534539A (en) 2006-02-24
WO2003068226A1 (en) 2003-08-21
US20040010022A1 (en) 2004-01-15
KR20040084905A (ko) 2004-10-06
DE60317632T2 (de) 2008-10-30
IL163110A (en) 2010-12-30

Similar Documents

Publication Publication Date Title
NO20032277D0 (no) Aminotiazoler og deres anvendelse som adenosinreseptorantagonister
NO20043536L (no) Fluorsubstituerte sykloalkanoindoler og deres anvendelse som prostaglandin D2-reseptorantagonister
DK1761529T3 (da) Pyrrolopyridinderivater og deres anvendelse som CRTh2-antagonister
NO20055238D0 (no) Kondenserte N-heterocykliske forbindelser og deres anvendelse som CRF-reseptorantagonister
CY2014018I2 (el) Kαρβαμιδο - υποκατεστημενες πυραζολοπυριδινες
IS7801A (is) Púrín efnasambönd og notkun þeirra sem kannabinóíð viðtaka bindla
NO20030471D0 (no) Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
NO20055135D0 (no) Fenylguinoliner og deres anvendelse som ostrogenreseptormodulatorer
DK2208727T3 (da) Diarylethere som opioidreceptorantagonister
DK1345920T3 (da) Hidtil ukendte sulfamider og anvendelse deraf som endothelinreceptorantagonister
NO20023283D0 (no) Flammestopper
NO20041008L (no) Karbazolderivater og anvendelse derav som NPY5 reseptor antagonister
DK1581518T3 (da) Substituerede 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazin-derivater og deres anvendelse som neurokinin antagonister
ATE432282T1 (de) 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten
DK1578727T3 (da) Tetrahydroquinolin-derivater og deres anvendelse som FSH-receptor-modulatorer
NO20044373L (no) Azetidinderivater som CCR-3-reseptorantagonister
ATE469875T1 (de) Nk1-antagonisten
NO20043366L (no) Kortikotropinfrigjorende faktor-2 reseptoragonister
ATE356124T1 (de) Hydroxyalkylsubstituierte pyrido-7-pyrimidin-7- one
NO20040499L (no) Substituerte pyridin-4-oner og deres andvendelse som gonadotropin-frigjorende hormon reseptor antagonister.
NO20043799L (no) 2-oksasolaminer og deres anvendelse som 5-HT2B reseptor antagonister
FI20060188L (fi) Modifioidut IL-4-muteiinin reseptorin antagonistit
DK1641787T3 (da) Substituerede diketopiperaziner og deres anvendelse som oxytocinantagonister
NO20053598L (no) Substituerte 1-piperidin-3-yl-4-pyrrolidin-4-yl-piperazinderivater og deres anvendelse som nevrokininantagonister.
NO20055725D0 (no) Glutamatreseptorantagonister som neurobeskyttende midler

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees